HomePalisade Bio CEO Tom Hallam Discusses Gastrointestinal Therapeutics
Palisade Bio CEO Tom Hallam Discusses Gastrointestinal Therapeutics

The CEO of Palisade Bio, Tom Hallam, says that the biopharma company is focused on gastrointestinal therapeutics. One of its drug candidates has shown that it can reduce hospital stays following surgery. PALI was formed from a merger between Leading BioSciences and Seneca Biopharma. The stock began trading on the Nasdaq today.

The Watch List

28 Apr 2021

ON AIR
6:00 am
Fast Market
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
ON AIR
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US